Comparative Approaches to Drug Pricing

被引:22
作者
Kang, So-Yeon [1 ]
Bai, Ge [1 ,2 ]
DiStefano, Michael J. [1 ]
Socal, Mariana P. [1 ]
Yehia, Farah [1 ]
Anderson, Gerard F. [1 ,3 ]
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Carey Business Sch, Baltimore, MD 21202 USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
来源
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 41 | 2020年 / 41卷
关键词
drug prices; external reference prices; drug innovation; ability to pay; access to pharmaceuticals; PRICES; PHARMACEUTICALS; COMPETITION; ASSISTANCE; COUNTRIES; STILL;
D O I
10.1146/annurev-publhealth-040119-094305
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries' approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.
引用
收藏
页码:499 / 512
页数:14
相关论文
共 67 条
[1]   It's Still The Prices, Stupid: Why The US Spends So Much On Health Care, And A Tribute To Uwe Reinhardt [J].
Anderson, Gerard F. ;
Hussey, Peter ;
Petrosyan, Varduhi .
HEALTH AFFAIRS, 2019, 38 (01) :87-95
[2]  
Anderson S, 2019, A U-ARCHIT URBAN, P19
[3]  
[Anonymous], 2008, Social value judgements: Principles for the development of NICE guidance
[4]  
[Anonymous], 2018, Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures
[5]  
[Anonymous], 2018, Generic Drug Facts
[6]  
[Anonymous], 2016, Tax Notes, V153, P1151
[7]  
Assoc. Access. Med, 2018, GEN DRUG ACC SAV
[8]  
Axis Advis. LLC, 2019, ANAL PBM SPREAD PRIC
[9]   Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing [J].
Bai, Ge ;
Sen, Aditi P. ;
Anderson, Gerard F. .
ANNALS OF INTERNAL MEDICINE, 2018, 168 (06) :436-+
[10]   US Hospitals Are Still Using Chargemaster Markups To Maximize Revenues [J].
Bai, Ge ;
Anderson, Gerard F. .
HEALTH AFFAIRS, 2016, 35 (09) :1658-1664